SSY Group's (HKG:2005) Bumetanide was approved for registration by China's National Medical Products Administration to become a bulk drug for preparation on the market, according to a Monday Hong Kong bourse filing.
Bumetanide is mainly used to treat edema associated with heart failure or renal or hepatic dysfunction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments